[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.92.62. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
January 22/29, 2003

Financial Consequences of Drug Benefit Plans

Author Affiliations
 

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2003;289(4):423-424. doi:10.1001/jama.289.4.423-a

To the Editor: Dr Joyce and colleagues1 found that insurance plans with either increased co-payments or mandatory generic substitutions had lower drug costs. They also found that such policies led to increased out-of-pocket costs for patients. However, their outcome measure (payments made by employer) may not be correct. Although other components of transaction data are typically well-defined in plan summary documents (eg, pharmacy dispensing fee, contracted discount off average wholesale price [AWP], and cost-sharing with patients), line-item drug ingredient price data from the health plan are often subject to interpretation.

First Page Preview View Large
First page PDF preview
First page PDF preview
×